Everything below concerns TH9507. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-21. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Zverev maintained his top 5 ranking throughout the year. However, he still did not deliver any high-calibre results at the major tournaments. He was upset at the Australian Open by reigning Next Gen Finals champion and No. 59 Chung Hyeon in five sets in the third round. Zverev stated that issues at majors were "definitely not physical" when asked if his problems were physical or mental, and also attribute this lack of success to the extra pressure he was putting on himself at these events. Zverev did not reach his first final of the year until early April at the Miami Masters. Despite taking the first set of the final, he finished runner-up to American John Isner, who had never previously won a Masters title. Zverev continued his Masters success into the clay-court season, reaching the semifinals at the Monte Carlo Masters, winning his third career Masters title at the Madrid Open, and making the final at the Rome Masters. In Madrid, he defeated Dominic Thiem in the final to become the only active player outside of the Big Four to have won three Masters titles. He came close to winning back-to-back Masters events, going up a break in the third set against Nadal at the Italian Open. However, Nadal was able to recover and win the final five games of the match after a rain delay. Zverev had also defended his title at the Bavarian International Tennis Championships in his only other French Open tune-up to help build up a 13 match win streak that lasted until the Italian Open final.
=== Metformin therapy === Metformin, a drug used for weight loss in diabetes patients, has been shown to reduce keto-isoaproic acid (KIC) in patient-derived fibroblasts as well as a murine model of MSUD. Metformin has also been shown to aid weight loss in MSUD patients who are at increased risk for obesity and related complications when following prescribed hyper-caloric diets to avoid metabolic decompensation.
When the fetus is exposed to testosterone, the genital tubercle elongates (primordial phallus) and develops into the glans and shaft of the penis and the urogenital folds fuse to become the penile raphe. The urethra within the penis (except within the glans) is developed from the urogenital sinus.
Sources: en.wikipedia.org
She had formerly had the same symptoms of arsenical poison herself, and it was some time before she discovered it to be the mesmeric work of an enemy. Soon after her marriage her husband began to manifest the same symptoms and had since shown them from time to time; but was, with her help, always able to overcome them. A few weeks ago she observed that he did not look well, and when questioned he said that he was unable to get the idea of this arsenical poison out of his mind. He had been steadily growing worse ever since, but still had hoped to overcome the trouble until the last. After the death the body had turned black. A doctor performed an autopsy and showed Eddy her husband's diseased heart, but she responded by giving more interviews about mesmerism. Fraser wrote that the articles made Eddy a household name, a real-life version of the charismatic and beautiful Verena Tarrant in Henry James's The Bostonians (1885–1886), with her interest in spiritualism, women's rights and the mind cure. Shortly after the death, Eddy moved next door to 571 Columbus Avenue with several students. The following year, 1883, she founded the Journal of Christian Science (later called the Christian Science Journal), which spread news of her ideas across the United States.
==== Dystrophic calcinosis cutis ==== Dystrophic calcinosis cutis is the most prevalent kind of calcification on the skin. The ectopic calcified mass usually consists of amorphous calcium phosphate and hydroxyapatite. Dystrophic calcification is linked to a number of illnesses, such as infections, hereditary diseases, cutaneous neoplasms, and connective tissue diseases. The clinical manifestation can be as minor as an accidental radiography imaging finding or as severe as subcutaneous nodules or plaques.
The debate continued for two days, mostly between TheJosh and Justin27. It narrowed down to a disagreement over if a week constitutes seven or eight days; Justin27 defined it as seven, from Sunday to Saturday, while TheJosh defined it as eight, from Sunday to the next Sunday. It then hinged on if Sunday was a "real day". English dictionaries universally define a week as having seven days, including Sunday. The two users' rhetoric intensified to where they were posting harsh insults, such as when Justin27 told TheJosh: "You are the dumbest boy alive. Jump off a bridge." After 120 posts across five web pages, the thread was locked by moderators, without the two coming to an agreement. TheJosh ended the debate by saying they had only been trolling, which SB Nation writer Jon Bois theorized was an attempt to maintain their dignity after being publicly embarrassed. As of 2016, the thread had 3 million page views since its creation. It had gone viral after being posted on Reddit in 2015. However, the debate "had been raging in the minds of" Bodybuilding.com's users since 2008. It was the subject of a 2016 SB Nation documentary titled The Dumbest Boy Alive by Bois, who referred to it as the "perhaps the dumbest argument in the history of the Internet". Deadspin writer Albert Burneko claimed it was "the least essential discussion ever had", and Chris Person said it was "the stuff of legends". In 2015, Vice magazine contacted U.S.-based mathematician Joanna Nelson for a resolution to the debate.
Sources: en.wikipedia.org
=== Anti-fouling paints === Metabolites produced by marine algae have been found to have many antimicrobial properties. This is because they are produced by the marine organisms as chemical deterrents and as such contain bioactive compounds. The principal classes of marine algae that produce these types of secondary metabolites are Cyanophyceae, Chlorophyceae and Rhodophyceae. Observed biogenic products include polyketides, amides, alkaloids, fatty acids, indoles and lipopeptides. For example, over 10% of compounds isolated from Lyngbya majuscula, which is one of the most abundant cyanobacteria, have antifungal and antimicrobial properties. Additionally, a study by Ren et al. (2002) tested halogenated furanones produced by Delisea pulchra from the Rhodophyceae class against the growth of Bacillus subtilis. When applied at a 40 μg/mL concentration, the furanone inhibited the formation of a biofilm by the bacteria and reduced the biofilm's thickness by 25% and the number of live cells by 63%. These characteristics then have the potential to be utilised in man-made materials, such as making anti-fouling paints without the environment-damaging chemicals. Environmentally safe alternatives are needed to TBT (tin-based antifouling agent) which releases toxic compounds into water and the environment and has been banned in several countries. A class of biogenic compounds that has had a sizeable effect against the bacteria and microalgae that cause fouling are acetylene sesquiterpenoid esters produced by Caulerpa prolifera (from the Chlorophyceae class), which Smyrniotopoulos et al.
=== Modulated drug release and zero-order drug release === Many scientists worked to create oral formulations that could maintain a constant drug level because of the ability of drug release at a zero-order rate blood's concentration. However, a few physiological restrictions made it challenging to create such oral formulations. First, because the lower parts of the intestine have a decreased capacity for absorption, the medication absorption typically declines as an oral formulation moves from the stomach to the intestine. The decreased drug amount released from the formulation over time frequently made this condition worse. Phenylpropanolamine HCl release from was the only instance of sustaining consistent blood concentration for roughly 16 hours.
A clinical biologist is a health professional such as a doctor of medicine, pharmacist, biologist that is specialized in clinical biology, a medical specialty derived from clinical pathology. The concept includes interventional biology, including assisted reproductive technology. These professionals follow a medical residency whose duration varies between countries (from 3 to 5 years). This term is frequently used in France, Switzerland, Belgium, and other countries in Western Europe, Africa or Asia.
Many proteins produced within the cell are secreted outside the cell to function as extracellular proteins. Extracellular proteins are exposed to a wide variety of conditions. To stabilize the 3D protein structure, covalent bonds are formed either within the protein or between the different polypeptide chains in the quaternary structure. The most prevalent type is a disulfide bond (also known as a disulfide bridge). A disulfide bond is formed between two cysteine amino acids using their side chain chemical groups containing a Sulphur atom, these chemical groups are known as thiol functional groups. Disulfide bonds act to stabilize the pre-existing structure of the protein. Disulfide bonds are formed in an oxidation reaction between two thiol groups and therefore, need an oxidizing environment to react. As a result, disulfide bonds are typically formed in the oxidizing environment of the endoplasmic reticulum catalyzed by enzymes called protein disulfide isomerases. Disulfide bonds are rarely formed in the cytoplasm as it is a reducing environment.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.